Vetter Introduces New Syringe Closure System for Highly-Sensitive Compounds

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-08-05-2015
Volume 11
Issue 8

Consisting of a needle hub and a needle shield, the new syringe closure system is partly produced by means of a two-component injection molding process of polypropylene and thermoplastic elastomer.

Vetter has launched a new closure system for prefilled syringes, Vetter-Ject. Developed with usability in mind, the system comes with tamper-evident features and can be used with highly sensitive compounds, such as biologics. Consisting of a needle hub and a needle shield, the new syringe closure system is partly produced by means of a two-component injection molding process of polypropylene and thermoplastic elastomer.

There is an increasing number of drug products consisting of sensitive and complex molecules. Such drugs require an injection system that is flexible, safe, and easy to handle. Vetter has developed Vetter-Ject to meet this demand.

The baked-in siliconization process for the glass barrel uses less silicone oil, making the system suitable for silicone-sensitive formulations. According to Vetter, the silicone content of the syringe can also be customized to specific requirements. The amount of silicone used, as well as the related particle load, can be reduced by up to 80% compared with the standard siliconization process applied to conventional syringe systems.

Vetter-Ject can be used with a wide range of primary packaging options, such as different stoppers and glass barrels. Vetter also provides complete sterile fill and finish services and offers as part of its packaging service the assembly and final packaging of Vetter-Ject syringe system-from trays and plunger rod assembly, to auto-injector assembly and final packaging.

Source: Vetter

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content